An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

DENVER — Early data for a new vaccine for pancreatic cancer is generating some hope among patients, researchers and doctors.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of contracting the disease.

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine ...

A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment ...

At present, no pancreatic cancer vaccine is available to the public. However, emerging research in recent years looks promising and could help doctors improve pancreatic cancer survival rates.

A one-size-fits-all vaccine has shown promising results in keeping hard-to-treat pancreatic cancers from coming back. The ...